Eisai Co., Ltd. (4523) Press Release
Notification Regarding Receipt of Dividend from a Consolidated Subsidiary
Earlier from Eisai
- U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
- Leqembi® Pen subcutaneous formulation approved in Japan
- LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease
- Eisai and Osaka Prefecture Enter into Collaboration to Promote Awareness of Dementia and Mild Cognitive Impairment (MCI)